Records, court filings and emails reveal how federal review of Enbridge's Great Lakes tunnel project leaves tribal officials ...

Biocon Ltd's arm, Biocon Biologics Ltd, has received European Commission authorisation for its Vevzuo and Evfraxy biosimilars ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has announced ...

Denosumab is a human monoclonal antibody that targets and binds a protein known as RANKL (Receptor Activator of Nuclear Factor Kappa-B Ligand).

Evfraxy® is authorised for the treatment of osteoporosis in men and postmenopausal women, the treatment of bone loss linked to hormone ablation in men with prostate cancer at increased risk of ...

Biocon Biologics was granted marketing authorisation by the European Commission for Vevzuo and Evfraxy biosimilars of Denosumab used in the treatment of different bone diseases.

"I asked my very experienced boss if he had ever seen that before, and he hadn't. So, I asked if he thought she was still ...

Biocon Biologics receives European Commission approval for Vevzuo and Evfraxy, biosimilars of Denosumab, used to treat ...

Denosumab biosimilars Vevzuo and Evfraxy are used for treating various bone diseases. The approvals mark a key step in the ...

Biocon Biologics receives marketing authorisation from the European Commission for two Denosumab biosimilars, Vevzuo and Evfraxy, for treating bone diseases and related conditions ...